Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation

[Image: see text] Preclinical evidence in support of the potential utility of mGlu(5) NAMs for the treatment of a variety of psychiatric and neurodegenerative disorders is extensive, and multiple such molecules have entered clinical trials. Despite some promising results from clinical studies, no sm...

Descripción completa

Detalles Bibliográficos
Autores principales: Felts, Andrew S., Rodriguez, Alice L., Blobaum, Anna L., Morrison, Ryan D., Bates, Brittney S., Thompson Gray, Analisa, Rook, Jerri M., Tantawy, Mohammed N., Byers, Frank W., Chang, Sichen, Venable, Daryl F., Luscombe, Vincent B., Tamagnan, Gilles D., Niswender, Colleen M., Daniels, J. Scott, Jones, Carrie K., Conn, P. Jeffrey, Lindsley, Craig W., Emmitte, Kyle A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484149/
https://www.ncbi.nlm.nih.gov/pubmed/28530802
http://dx.doi.org/10.1021/acs.jmedchem.7b00410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484149/
https://www.ncbi.nlm.nih.gov/pubmed/28530802
http://dx.doi.org/10.1021/acs.jmedchem.7b00410

Ejemplares similares